Navigation Links
Luminex Announces Commercial Launch of New Cystic Fibrosis Test
Date:8/26/2010

AUSTIN, Texas, Aug. 26 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, today announced the full commercial launch of its xTAG® Cystic Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.  

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)

The test is the most comprehensive and flexible FDA-cleared cystic fibrosis (CF) test available, featuring an unsurpassed level of gene mutation coverage.  It will be used to screen potential parents to determine if they are carriers of CF-causing gene mutations, and as an aid in newborn screening and in confirmatory diagnostic testing in newborns and children.  The test recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

"The launch of our new xTAG Cystic Fibrosis 60 Kit v2 is a great achievement in cystic fibrosis testing," said Patrick J. Balthrop, president and chief executive officer of Luminex. "This cleared test has the most comprehensive genetic mutation coverage available today, featuring mutations found among Caucasians as well as those that are more commonly found in other ethnic populations.  It will give doctors the ability to screen children and potential parents of many ethnicities for CF."

Cystic fibrosis is a common genetic disorder that causes the body to produce thick mucus that can clog the lungs and affect the digestive system.  Approximately 30,000 Americans have cystic fibrosis.  Although CF is most common in those of Caucasian desce
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014   Acutus Medical, ... invasive real-time 3D Cardiac Chamber Imaging and Dipole Density ... / or sustain complex cardiac arrhythmias, including atrial fibrillation, ... continue developing its imaging/mapping system as well as bring ... allow Acutus Medical to complete work on the AcQMap ...
(Date:9/30/2014)... , Sept. 30, 2014 In 2011, approximately ... abused prescription pain relievers (e.g. opioids). 1 ... maintenance treatment, which entails the use of buprenorphine, buprenorphine/naloxone, ... treatments are important when developing and improving care management ... benefit manager Prime Therapeutics LLC (Prime). ...
(Date:9/30/2014)... , Sept. 30, 2014  Life Science Angels ... on supporting promising emerging biotech, medical device, genomics, ... the Top Angel Investment Group in the U.S.  ... best performer out of 370 angel groups analyzed ... network strength (connections), selection aptitude and brand recognition.  ...
Breaking Medicine Technology:Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3Life Science Angels Ranked the Top Angel Investment Group in the U.S. 2Life Science Angels Ranked the Top Angel Investment Group in the U.S. 3
... Thousands of jobs in Ohio supported by the biopharmaceutical ... such as imposing new taxes in the Medicare prescription ... From research to technical work, manufacturing to construction ... services, the biopharmaceutical sector supports a broad array of ...
... 27, 2011 Codexis, Inc. (Nasdaq: CDXS ... of a joint development agreement to develop an improved ... is Brazil,s largest sugar and ethanol producer.   ... Codexis will deploy the Codexis CodeEvolver™ directed evolution technology ...
Cached Medicine Technology:Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 3Codexis, Raizen to Develop First Generation Ethanol 2Codexis, Raizen to Develop First Generation Ethanol 3
(Date:9/30/2014)... Pittsburgh School of Dental Medicine have been awarded a ... Dental and Craniofacial Research, part of the National Institutes ... roots of cleft lip and cleft palate and to ... the Philippines and Pennsylvania. , Orofacial clefts (OFCs), ... that can form when a baby,s mouth doesn,t develop ...
(Date:9/30/2014)... that some stickleback fish fathers can have long-term effects ... fish dads cause their offspring to behave in a ... behavioral changes are accompanied by changes in gene expression, ... in the Proceedings of the Royal Society B: ... that moms are very important for their offspring," said ...
(Date:9/30/2014)... RISC Networks Corporation, the leader ... data center, cloud and core network infrastructure. RISC ... of helping more than 5,000 businesses solve complex ... as IT infrastructure transformation, cloud IaaS and data ... engagement rates and partner growth seen in 2014 ...
(Date:9/30/2014)... 30, 2014 Speaking on this occasion, ... observed ‘Nursing Conference’ as a remarkable event, which brings ... medical and clinical research and diagnostic companies, leading universities ... a perfect platform to share experience, foster collaborations across ... world. Nursing Conference is a forum to explore issues ...
(Date:9/30/2014)... 2014 MyMobileUni seeks to partner globally ... have similar shared vision to transform individuals and empower ... (MMU):, , to impact ... all ages , to have focused channels ... to promote equal access to education and ...
Breaking Medicine News(10 mins):Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 3Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 2Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 3Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 2Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 3
... Dec. 7 Transcept Pharmaceuticals,Inc. today announced that Glenn ... an expert panel on "Drug Development in a,Changed Environment" ... Westin New York Hotel at Times Square on Thursday, ... multi-company panel will be moderated by Ken Trbovich, Vice,President, ...
... Ventures, a health and life,sciences focused venture capital firm ... of the firm., "We are pleased to name ... Partner of Radius. "David has demonstrated an outstanding,ability to ... have his,energy and continued contribution as we develop Radius ...
... one of the commonest surgical procedures performed on ... both physical and psychological harm, while recent evidence ... debate the issue in this weeks BMJ. , ... infant circumcision, yet ritual (non-therapeutic) male circumcision continues ...
... inadequate and should be replaced with charters of health ... But even these raise ethical tensions, says Harald Schmidt, ... Medical Association (BMA) recently called for a charter setting ... Service and what patients can expect from the NHS. ...
... 7 Bond,Laboratories, Inc. (OTC Bulletin Board: BNDB), a ... file with the NASD to implement,a 2-for-1 forward split ... as of the record date will receive,two (2) shares ... For,example, shareholders owning 5,000 shares prior to the stock ...
... REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, December 7, ... in,the development of microRNA-based diagnostics and therapeutics, announced,today that ... Rosetta Genomics,will present at RBC Capital Markets 2007 Healthcare ... the Westin Hotel in New York., A live ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference 2Health News:Is infant male circumcision an abuse of the rights of the child? 2Health News:Concept of patients' charters 'inadequate' 2Health News:Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2007 Healthcare Conference 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: